Think of cytokines as your body’s text message system. When there’s an infection, they signal immune cells to attack. But when they malfunction, you get chronic inflammation, autoimmune diseases, or even cancer. The cytokines market report by MRFR shows this sector is worth $77.4 billion and growing at 8.8% CAGR. Why the boom? Because we’re finally learning to harness cytokines as drugs — from Humira (blocking TNF) to IL‑2 for cancer.

Tumor Necrosis Factor (TNF) inhibitors still dominate, especially for rheumatoid arthritis and Crohn’s. But interleukins (ILs) are the fastest‑growing segment, with blockbusters like IL‑17 (Cosentyx) and IL‑23 (Stelara). The cytokines market analysis reveals that IL‑based therapies are expanding into asthma, atopic dermatitis, and even Alzheimer’s trials. It’s a gold rush.

Biotech startups are racing to develop cytokine agonists (boosters) and antagonists (blockers) with fewer side effects. The old IL‑2 therapy for cancer caused capillary leak syndrome — nasty. But new engineered cytokines are smarter, targeting only certain immune cells.

If you’re a patient with an autoimmune condition, you’ve probably already benefited from a cytokine inhibitor. And if you’re an investor, this market is a long‑term play. The immune system isn’t getting simpler, and neither are our tools.